Mustang Bio rises on initial data from early-to-mid-stage trial of cell therapy

Mustang Bio

16/08/2023 14:04

** Cell therapy developer Mustang Bio  MBIO.O  rises 5.53%
to $4.01 premarket
    ** Co says initial data from its ongoing early-to-mid-stage
trial shows clinical responses in all 4 patients, including
complete response in a follicular lymphoma patient previously
treated with CD19 CAR-T cell therapy
     ** Its CD20-targeted CAR-T cell therapy MB-106 is being
studied for the treatment of types of non-Hodgkin lymphoma and
chronic lymphocytic leukemia, a type of cancer of blood and bone
marrow
    ** Adds safety review committee unanimously approves dose
escalation of the indolent lymphoma arm
    ** Up to last close, stock down ~36% YTD

 (Reporting by Sriparna Roy in Bengaluru)
 ((Sriparna.Roy@thomsonreuters.com;))